Biotech News

Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

Seer, Inc (SEER)Seer, IncCompany update

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok’s Short-Term Campaign Risks Disrupting Seer’s Momentum and Undermines Stockholder Value Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the

Related news

Seer, Inc

Deep Proteomics Company Seer develops tools for large-scale, unbiased analysis of the proteome across research, translational medicine, and drug development. Proteograph Product Suite The Proteograph platform combines engineered nanoparticles, automated sample processing, consumables, and analytical software to capture proteins across a...

Recent company news

Stock data

Close
2.03 USD
Market cap
102.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States